Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

British Journal of Dermatology

Volumn 144, Issue 3, 2001, Pages 587-589

  Ogilvie, A L J ^a   Antoni, C ^a   Dechant, C ^a   Manger, B ^a   Kalden, J R ^a   Schuler, G ^a   Lüftl, Matthias ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Antitumour necrosis factor antibody; Infliximab; Psoriasis; Psoriasis Area and Severity Index; Psoriatic arthritis; Tumour necrosis factor

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DERMATOLOGIC AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE; HUMANS; METHOTREXATE; PSORIASIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035083651     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.04089.x     Document Type: Article

References (12)

1. Epidemiologic aspects of psoriasis and arthritis
2. The pathogenesis of psoriasis: Immunological facts and speculations
3. Inflammatory skin diseases, T cells, and immune surveillance
4. The Psoriasis Area and Severity Index and alternative approaches for the assessment of severity: Persisting areas of confusion
5. Successful treatment of severe psoriatic arthritis with infliximab
6. T cells involved in psoriasis vulgaris belong to the Th1 subset
7. The role of superantigens in human diseases: Therapeutic implications for the treatment of skin diseases
8. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions
9. Methotrexate therapy of psoriasis: Differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate
10. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
11. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study
12. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions